Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control
Rev. bras. pesqui. méd. biol
; Braz. j. med. biol. res;55: e12235, 2022. tab
Article
de En
|
LILACS-Express
| LILACS
| ID: biblio-1403894
Bibliothèque responsable:
BR1.1
ABSTRACT
Convalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with contemporaneous controls in a hospital in southern Brazil. Patients were selected for treatment with convalescent plasma by medical decision and compared with patients who did not receive plasma and were hospitalized due to COVID-19 at the same time. The outcomes of interest were intensive care unit (ICU) admission and in-hospital death. Patients that received convalescent plasma had lower in-hospital mortality than patients that did not receive plasma (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29 to 0.79) and these results were consistent after changing the subset of control patients. There were no differences regarding ICU admission between groups (RR=0.80; 95%CI 0.47 to 1.35). In this study, patients that received convalescent plasma for COVID-19 had lower in-hospital mortality, but this finding requires further confirmation given the retrospective nature of the study.
Texte intégral:
1
Indice:
LILACS
Type d'étude:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
langue:
En
Texte intégral:
Braz. j. med. biol. res
/
Rev. bras. pesqui. méd. biol
Thème du journal:
BIOLOGIA
/
MEDICINA
Année:
2022
Type:
Article